---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-113275"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T11:16:44.200189+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aldeyra reproxalap meets primary endpoint in Phase 3 dry eye chamber trial; NDA resubmission planned mid-2025

## Summary
- Reproxalap statistically superior to vehicle on ocular discomfort (LS mean diff -6.5, P=0.002) in Phase 3 chamber trial (n=58 per arm).
- No notable baseline differences across treatment arms; Aldeyra believes data address FDA CRL from April 2025.
- NDA resubmission anticipated mid-2025 pending Type A meeting; review expected six months.
- A recent field trial was numerically supportive but did not reach statistical significance; will be submitted as supportive.
- No safety signals or treatment-related discontinuations; reproxalap well tolerated in over 2,900 patients studied.

## SEC filing metadata
- accession: 0001193125-25-113275
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000119312525113275/0001193125-25-113275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000119312525113275/d941544d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-113275
- JSON: https://secwatch.observer/filing/0001193125-25-113275.json
- Plain text: https://secwatch.observer/filing/0001193125-25-113275.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.